Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362309 · ClinicalTrials.gov registry record · NA
D-Cycloserine to Enhance Extinction to Alcohol Cues
A NA study, sponsored by University of Georgia.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT01362309 is a NA study that has completed, run by University of Georgia. The registered enrollment target is 37 participants.
The verdict
NCT01362309, a NA study, has completed, sponsored by University of Georgia.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
There is considerable evidence that Alcohol Use Disorders (AUDs) can be understood as a form of dysregulated learning and are influenced by classical conditioning. This is based on numerous studies indicating that conditioned contextual cues influence craving for alcohol consumption. As a result, there has been considerable interest in extinction-based treatments for AUDs (i.e., treatments that focus on extinguishing the associations between alcohol cues and motivation to drink), referred to as cue exposure treatment To date, extinction-based treatment for AUDs has resulted in disappointing outcomes in clinical trials and there is considerable interest in improving this form of treatment. One novel strategy is the use of pharmacological adjuncts to enhance extinction. Medications that maximize extinction may minimize subsequent reactions to alcohol cues and, in turn, subsequent clinical outcomes. This study is examining whether the medication d-cycloserine (DCS) can enhance extinction to alcohol cues. Recent basic research has revealed that DCS enhances extinction to fear cues and several lines of evidence suggest that DCS may also enhance extinction to alcohol cues. Therefore, DCS may serve as a useful pharmacological adjunct to extinction-based treatment for AUDs. Our primary aim is to examine whether, compared to placebo, DCS (50 mg) will enhance extinction to alcohol cues under controlled laboratory conditions in treatment-seeking individuals with alcohol use disorders. We hypothesize that DCS will generate greater extinction compared to placebo during the subsequent extinction session as measured by attenuated craving in response to alcohol cues. Furthermore, we hypothesize that DCS will generate greater extinction compared to placebo at follow-up assessments. This study is a proof-of-concept test of whether DCS can reduce reactions to alcohol cues under controlled laboratory conditions. It is a preliminary study using a subclinical number of extinction session
Interventions
- DRUG d-cycloserine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01362309
The ClinicalTrials.gov registry entry for NCT01362309 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Georgia, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which d-cycloserine. is the first listed.
NCT01362309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01362309 about?
NCT01362309 is a clinical study titled "D-Cycloserine to Enhance Extinction to Alcohol Cues". There is considerable evidence that Alcohol Use Disorders (AUDs) can be understood as a form of dysregulated learning and are influenced by classical conditioning. This is based on numerous studies indicating that conditioned contextual cues influence craving for alcohol consumption. As a result, th...
What is the current status of trial NCT01362309?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2010-11. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01362309?
The interventions under investigation include: d-cycloserine. (DRUG).
Who is sponsoring clinical trial NCT01362309?
This trial is sponsored by University of Georgia, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.